Abstract:Experimentalallergic encephalomyelitis(EAE) is an animal model for inflammatory demyelinating autoimmune disease, i.e., multiple sclerosis (MS). In the present study, we investigated the antineuroinflammatory/neuroprotective effects of C16, an alpha upsilon beta 3 integrin-binding peptide, and recombinant rat ciliary neurotrophic factor (CNTF), a cytokine that was originally identified as a survival factor for neurons, in an acute rodent EAE model. In this model, C16 peptide was injected intravenously every day for 2 weeks, and CNTF was delivered into the cerebral ventricles with Alzet miniosmotic pumps. Disease severity was assessed weekly using a scale ranging from 0 to 5. Multiple histological and molecular biological assays were employed to assess inflammation, axonal loss, neuronal apoptosis, white matter demyelination, and gliosis in the brain and spinal cord of different groups. Our results showed that the EAE induced rats revealed a significant increase in inflammatory cells infiltration, while C16 treatment could inhibit the infiltration of leukocytes and macrophages down to 2/3-1/3 of vehicle treated EAE control (P < 0.05). The delayed onset of disease, reduced clinical score (P < 0.01) in peak stage and more rapid recovery also were achieved in C16 treated group. Besides impairing inflammation, CNTF treatment also exerted direct neuroprotective effects, decreasing demyelination and axon loss score (P < 0.05 versus vehicle treated EAE control), and reducing the neuronal death from 40 to 50% to 10 to 20% (P < 0.05). Both treatments suppressed the expression of cytokine tumor necrosis factor-alpha and interferon-gamma when compared with the vehicle control (P < 0.05). Combined treatment with C16 and CNTF produced more obvious functional recovery and neuroprotective effects than individually treatment (P < 0.05). These results suggested that combination treatment with C16 and CNTF, which target different neuroprotection pathways, may be an effective therapeutic alternative to traditional therapy.

Treatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathways

VCAM-1+ Mesenchymal Stem/Stromal Cells Reveal Preferable Efficacy Upon an Experimental Autoimmune Encephalomyelitis Mouse Model of Multiple Sclerosis over the VCAM-1− Counterpart

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Role of C16, angiopoietin-1 and regeneration gene protein 2 in attenuating inflammation in an experimental rat model of autoimmune encephalomyelitis.

The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Combination of Apoptotic T Cell Induction and Self-Peptide Administration for Therapy of Experimental Autoimmune Encephalomyelitis

Anti-MS4a4B treatment abrogates MS4a4B-mediated protection in T cells and ameliorates experimental autoimmune encephalomyelitis (51.13)

Interleukin-27 Gene Therapy Prevents the Development of Autoimmune Encephalomyelitis but Fails to Attenuate Established Inflammation Due to the Expansion of CD11b+Gr-1+ Myeloid Cells

Anti-MS4a4B Treatment Abrogates MS4a4B-mediated Protection in T Cells and Ameliorates Experimental Autoimmune Encephalomyelitis.

CD4+CD25+ regulatory T cells ex vivo generated from autologous naïve CD4+ T cells suppress EAE progression

Combined Treatment with Minocycline and Prednisone Attenuates Experimental Autoimmune Encephalomyelitis in C57 BL/6 Mice.

Repeated Systemic Dosing of Adeno-Associated Virus Vectors in Immunocompetent Mice After Blockade of T Cell Costimulatory Pathways

Anlotinib Attenuates Experimental Autoimmune Encephalomyelitis Mice Model of Multiple Sclerosis Via Modulating the Differentiation of Th17 and Treg Cells.

Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α

Mycophenolate Mofetil Improves Neurological Function and Alters Blood T-lymphocyte Subsets in Rats with Experimental Autoimmune Encephalomyelitis.

Accelerated and Enhanced Effect of Ccr5-Transduced Bone Marrow Neural Stem Cells on Autoimmune Encephalomyelitis

CCDC134 Ameliorated Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells

Methyl Butyrate Alleviates Experimental Autoimmune Encephalomyelitis and Regulates the Balance of Effector T Cells and Regulatory T Cells

Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression